
Summit Therapeutics fell 30.3% from $16.95 to $11.82, behind the S&P 500's +11.2%. Its worst day was May 1 (−24.9%), and its low came Nov 16 at $11.82.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Summit Therapeutics shares fell 13.4%, while the S&P 500 rose 0.2%.
−13.4% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
EPS of $-0.14 missed the $-0.10 estimate on $0.00 revenue (est. $56.8M).
+0.2% · S&P 500 +0.7%
Summit Therapeutics shares rose 15.4%, while the S&P 500 rose 0.6%.
+15.4% · S&P 500 +0.6%
Summit Therapeutics closed at its highest level of the year, 55.6% above where the year started.
+5.0% · S&P 500 −0.7%
EPS of $-0.15 beat the $-0.23 estimate on $0.00 revenue (est. $40,850.00).
−24.9%, the year's worst day · S&P 500 +0.3%
Summit Therapeutics shares rose 12.9%, while the S&P 500 rose 1.0%.
+12.9% · S&P 500 +1.0%
EPS of $-0.19 beat the $-0.22 estimate on $0.00 revenue (est. $88,500.00).
−8.8% · S&P 500 +0.1%
Summit Therapeutics shares rose 17.3%, while the S&P 500 rose 1.0%.
+17.3%, the year's best day · S&P 500 +1.0%
EPS of $-0.20 beat the $-0.22 estimate on $0.00 revenue (est. $53,790.00).
−12.2% · S&P 500 −4.4%
Where it ended: a close of $11.82 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 22, 2027 (EPS est. $-0.24, revenue est. $3.1M).
Nothing in the past 12 months.
All SMMT dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SMMT and SPY from Benzinga historical bars. Not investment advice.